CELC - セルクイティ― (Celcuity Inc.) セルクイティ―

 CELCのチャート


 CELCの企業情報

symbol CELC
会社名 Celcuity Inc (セルクイティ―)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical Specialities  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 セルクイティ(Celcuity Inc.)は細胞分析会社である。同社は、標的治療法で治療されたがん患者の臨床転帰を有意に改善するために設計された新しいがんサブタイプの発見と診断テストの商品化に焦点を当てる。同社独自のCELx診断プラットフォームは、患者の生存している腫瘍細胞を使用して、患者の癌を引き起こす特定の異常細胞プロセスと、それを最もよく治療する標的療法を特定する。CELxプラットフォームは伝統的な分子診断を提供し、死んだ細胞を分析するため患者の腫瘍に存在する遺伝子変異のスナップショットを提供する。死んだ細胞を使用することは、分子診断がリアルタイムで、細胞増殖または生存を調節する細胞シグナリングとして知られる動的細胞活性を分析することを妨げる。   セルクイティ―は米国の医療診断企業。主にがん治療における細胞分析による診断試験の開発・商業化に従事する。同社のCELx診断プラットフォ―ムは、患者の腫瘍細胞を使用して、がんを引き起こす異常細胞プロセスと、それを治療する標的療法を特定する。患者の細胞機能不全に適合し、阻害する治療薬を選択することが可能になる。本社所在地はミネソタ州ミネアポリス。   Celcuity is a clinical stage biotechnology company translating discoveries of new cancer sub-types into pioneering companion diagnostics and expanded therapeutic options for cancer patients. Celcuity's 3rd generation diagnostic platform, CELsignia, analyzes living tumor cells to untangle the complexity of the cellular activity driving a patient's cancer. This allows Celcuity to discover new cancer sub-types molecular diagnostics cannot detect. Celcuity is driven to improve outcomes for patients and to transform how pharmaceutical companies define the patient populations for their targeted therapies. Celcuity is headquartered in Minneapolis, MN.
本社所在地 16305 36th Avenue North Suite 450 Minneapolis MN 55446 USA
代表者氏名
代表者役職名
電話番号 +1 763-392-0767
設立年月日 2011年
市場名 NASDAQ Small Cap
ipoyear 2017年
従業員数
url www.celucity.com
nasdaq_url https://www.nasdaq.com/symbol/celc
adr_tso
EBITDA EBITDA(百万ドル) -7.20995
終値(lastsale) 27.05
時価総額(marketcap) 273727389.6
時価総額 時価総額(百万ドル) 286.17410
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 264.64434
当期純利益 当期純利益(百万ドル) -7.63858
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Celcuity Inc revenues was not reported. Net loss increased 37% to $3.8M. Higher net loss reflects Research_Development - Balancing value increase of 44% to $2.8M (expense) General_Administrative - Balancing v increase from $258K to $638K (expense) Stock-Based Compensation increase from $129K to $275K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.29 to -$0.37.

 CELCのテクニカル分析


 CELCのニュース

   Celcuity Inc.: Celcuity to Participate in Cowen''s 43rd Annual Health Care Conference  2023/03/01 13:02:00 Finanz Nachrichten
MINNEAPOLIS, MN / ACCESSWIRE / March 1, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced its par…
   Celcuity to Participate in Cowen''s 43rd Annual Health Care Conference  2023/03/01 13:00:00 Accesswire
MINNEAPOLIS, MN / ACCESSWIRE / March 1, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced its participation in Cowen''s 43rd Annual Health Care Conference to be held in Boston on March 6-8, 2023. Brian Sullivan, Chief Executive Officer and co-founder of Celcuity, is scheduled to present at 11:10 a.m. ET on Wednesday, March 8, 2023. A live webcast of the presentation will be available using this weblink: https://wsw.com/webcast/cowen132/celc/1975134 . Alternatively, the live webcast will be accessible from the Investors section of the company''s website at https://ir.celcuity.com/events-presentations/ with a replay available shortly after the live event. About Celcuity Celcuity is a clinical-stage biotechnology company focused on development of targeted therapies for treatment of multiple solid tumor indications. The company''s lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTOR inhibitor.
   Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers Symposium  2023/02/16 13:00:00 Accesswire
Gedatolisib demonstrated superior potency and efficacy in prostate cancer cell lines compared to other PI3K/AKT/mTOR inhibitors evaluated regardless of PI3K or PTEN status MINNEAPOLIS, MN / ACCESSWIRE / February 16, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today presented data from preclinical studies evaluating gedatolisib and other PI3K/AKT/mTOR inhibitors in prostate cancer cell lines. The poster was presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), which is being held February 16-18, 2023. The presentation titled "Therapeutic effect of gedatolisib, a pan-PI3K/mTOR inhibitor, on prostate cancer models with PI3K or PTEN mutational status" demonstrated gedatolisib''s superior potency and efficacy across different prostate cancer cell lines relative to other PI3K/AKT/mTOR inhibitors of PTEN or PI3K status. "The findings further demonstrate gedatolisib''s differentiated mechanism of action and potential to treat various solid tumor types," said Brian Sullivan, Celcuity''s Chief Executive Officer and co-founder. "The results suggest that gedatolisib may help overcome or prevent development of resistance to androgen receptor inhibitors, which is particularly relevant in metastatic castration resistant prostate cancer (mCRPC)." This poster is available on the publications page of the Celcuity website.
   SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Celcuity Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors  2022/12/20 17:10:00 PR Newswire
NEW YORK, Dec. 20, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Celcuity Inc. (NASDAQ: CELC). If you are a…
   Celcuity Inc.: Celcuity Closes $100 Million Private Placement  2022/12/12 12:38:00 Finanz Nachrichten
MINNEAPOLIS, MN / ACCESSWIRE / December 12, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company, today announced the closing of its private placement, resulting in gross proc…
   Celcuity Inc.: Celcuity to Participate in Cowen''s 43rd Annual Health Care Conference  2023/03/01 13:02:00 Finanz Nachrichten
MINNEAPOLIS, MN / ACCESSWIRE / March 1, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced its par…
   Celcuity to Participate in Cowen''s 43rd Annual Health Care Conference  2023/03/01 13:00:00 Accesswire
MINNEAPOLIS, MN / ACCESSWIRE / March 1, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced its participation in Cowen''s 43rd Annual Health Care Conference to be held in Boston on March 6-8, 2023. Brian Sullivan, Chief Executive Officer and co-founder of Celcuity, is scheduled to present at 11:10 a.m. ET on Wednesday, March 8, 2023. A live webcast of the presentation will be available using this weblink: https://wsw.com/webcast/cowen132/celc/1975134 . Alternatively, the live webcast will be accessible from the Investors section of the company''s website at https://ir.celcuity.com/events-presentations/ with a replay available shortly after the live event. About Celcuity Celcuity is a clinical-stage biotechnology company focused on development of targeted therapies for treatment of multiple solid tumor indications. The company''s lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTOR inhibitor.
   Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers Symposium  2023/02/16 13:00:00 Accesswire
Gedatolisib demonstrated superior potency and efficacy in prostate cancer cell lines compared to other PI3K/AKT/mTOR inhibitors evaluated regardless of PI3K or PTEN status MINNEAPOLIS, MN / ACCESSWIRE / February 16, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today presented data from preclinical studies evaluating gedatolisib and other PI3K/AKT/mTOR inhibitors in prostate cancer cell lines. The poster was presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), which is being held February 16-18, 2023. The presentation titled "Therapeutic effect of gedatolisib, a pan-PI3K/mTOR inhibitor, on prostate cancer models with PI3K or PTEN mutational status" demonstrated gedatolisib''s superior potency and efficacy across different prostate cancer cell lines relative to other PI3K/AKT/mTOR inhibitors of PTEN or PI3K status. "The findings further demonstrate gedatolisib''s differentiated mechanism of action and potential to treat various solid tumor types," said Brian Sullivan, Celcuity''s Chief Executive Officer and co-founder. "The results suggest that gedatolisib may help overcome or prevent development of resistance to androgen receptor inhibitors, which is particularly relevant in metastatic castration resistant prostate cancer (mCRPC)." This poster is available on the publications page of the Celcuity website.
   SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Celcuity Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors  2022/12/20 17:10:00 PR Newswire
NEW YORK, Dec. 20, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Celcuity Inc. (NASDAQ: CELC). If you are a…
   Celcuity Inc.: Celcuity Closes $100 Million Private Placement  2022/12/12 12:38:00 Finanz Nachrichten
MINNEAPOLIS, MN / ACCESSWIRE / December 12, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company, today announced the closing of its private placement, resulting in gross proc…
   Celcuity Appoints Polly Murphy, D.V.M., Ph.D., to Board of Directors  2022/09/14 13:00:00 Wallstreet:Online
Seasoned executive brings over two decades of pharmaceutical business development and commercial strategy experience to Celcuity''s Board of DirectorsMINNEAPOLIS, MN / ACCESSWIRE / September 14, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage …
   Celcuity Inc. (CELC) CEO Brian Sullivan on Q2 2022 Results - Earnings Call Transcript  2022/08/13 12:14:05 Seeking Alpha
Celcuity Inc. (NASDAQ:NASDAQ:CELC) Q2 2022 Earnings Conference Call August 11, 2022 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners, LLC Brian Sullivan - Co-Founder,…
   Celcuity Inc. 2022 Q2 - Results - Earnings Call Presentation (NASDAQ:CELC)  2022/08/12 00:59:41 Seeking Alpha
The following slide deck was published by Celcuity Inc.
   Celcuity: Q2 Earnings Insights  2022/08/11 20:21:40 Benzinga
Celcuity (NASDAQ: CELC ) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:00 PM. Here''s what investors need to know about the announcement. Earnings Celcuity missed estimated earnings by 10.0%, reporting an EPS … Full story available on Benzinga.com
   Celcuity GAAP EPS of -$0.55  2022/08/11 20:04:36 Seeking Alpha
Celcuity press release (CELC): Q2 GAAP EPS of -$0.55.At June 30, 2022, Celcuity had cash and cash equivalents of $66.9 million, compared to cash and cash equivalents of $84.3 million…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 セルクイティ― CELC Celcuity Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)